Case 4: 67-Year-Old Woman With Intrahepatic Cholangiocarcinoma
Watch
Case 3: Downstaging and Increased Survival in HCC
Case 3: Radioembolization, Alternative To Chemoembolization in HCC
Case 3: 68-Year-Old Man With Borderline Resectable HCC
Case 2: Choosing the Right Treatment Option
Case 2: Second-Line Therapy Options for HCC
Case 2: 67-Year-Old Woman With Refractory HCC
Case 1: Treatment Response Rates & the Role of IR
Case 1: Treatment Considerations for Recurrent mHCC
Case 1: Criteria for Surgery vs RFA vs Transplant in HCC
Case 1: 58-Year-Old Man With Newly Diagnosed HCC
Hepatocellular Carcinoma
Additional Insights: Experience with FGFR Inhibitors in Bladder Cancer
Additional Insights: Collaborative Approach to Bladder Cancer
Additional Insights: FGFRi-Associated Ocular AEs in Bladder Cancer
Case 4: Considering Special Populations in Bladder Cancer
Case 4: Multiple Lines of Therapy in Recurrent Bladder Cancer
Case 4: MUC With Non-Muscle Invasive Recurrence
Case 3: Experience With FGFR-Targeted Therapies in Bladder Cancer
Case 3: FGFR-Targeted Therapy Adverse Events in Bladder Cancer
Case 3: Mutational Patterns in Bladder Cancer
Case 3: Molecular Testing in Bladder Cancer
Case 3: Treatment for FGFR3+ Bladder Cancer
Case 3: Relapsed Muscle-Invasive Bladder Cancer, FGFR3+
Case 2: I-O Therapy for Cisplatin-Ineligible Bladder Cancer
Case 2: Exciting New Treatment for Cis-Ineligible Bladder Cancer
Case 2: Combination Therapy for Cis-Ineligible Bladder Cancer
Case 2: Factors in Treating Cis-Ineligible Bladder Cancer
Case 2: Cisplatin-Ineligible Metastatic Bladder Cancer
Case 1: Novel Agents in Superficial Bladder Cancer
